Search Results - Andrzej Jakubowiak

Refine Results
  1. 1
    Evolution of carfilzomib dose and schedule in patients with multiple myeloma: A historical overview

    Evolution of carfilzomib dose and schedule in patients with multiple myeloma: A historical overview by Andrzej Jakubowiak

    Published 2014
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  2. 2
    Differential Effects of Gonadotropin-Releasing Hormone (GnRH) Pulse Frequency on Gonadotropin Subunit and GnRH Receptor Messenger Ribonucleic Acid Levels in Vitro*

    Differential Effects of Gonadotropin-Releasing Hormone (GnRH) Pulse Frequency on Gonadotropin Subunit and GnRH Receptor Messenger Ribonucleic Acid Levels in Vitro* by Ursula B. Kaiser, Andrzej Jakubowiak, Anna Steinberger, William W. Chin

    Published 1997
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  3. 3
    Monoclonal antibodies in the treatment of multiple myeloma

    Monoclonal antibodies in the treatment of multiple myeloma by Paul G. Richardson, Sagar Lonial, Andrzej Jakubowiak, Jean‐Luc Harousseau, Kenneth C. Anderson

    Published 2011
    Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma

    Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma by Ola Landgren, Pieter Sonneveld, Andrzej Jakubowiak, Mohamad Mohty, Karim Iskander, Khalid Mezzi, David S. Siegel

    Published 2019
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis

    Racial differences in treatment and outcomes in multiple myeloma: a multiple myeloma research foundation analysis by Benjamin A. Derman, Jagoda Jasielec, Spencer S. Langerman, Wei Zhang, Andrzej Jakubowiak, Brian C.‐H. Chiu

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  6. 6
    Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation

    Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous ste... by Benjamin A. Derman, Andrew Stefka, Ken Jiang, Amanda McIver, Tadeusz Kubicki, Jagoda Jasielec, Andrzej Jakubowiak

    Published 2021
    Get full text Get full text
    Carta
    Save to List
    Saved in:
  7. 7
    Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia

    Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia by Lisa Kujawski, Peter Ouillette, Harry P. Erba, Chris Saddler, Andrzej Jakubowiak, Mark Kaminski, Kerby Shedden, Sami N. Malek

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  8. 8
    Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective

    Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective by Andrzej Jakubowiak, Marco Campioni, Ágnes Benedict, Ivan Houisse, Eszter Tichy, Andromachi Giannopoulou, Sanjay Aggarwal, Beth Barber, Sumeet Panjabi

    Published 2016
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  9. 9
    Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

    Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP) by Benjamin A. Derman, Ajay Major, Jennifer H. Cooperrider, Ken Jiang, Aubrianna Ramsland, Theodore Karrison, Tadeusz Kubicki, Andrzej Jakubowiak

    Published 2024
    Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma

    Phase I Trial of Anti-CS1 Monoclonal Antibody Elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple Myeloma by Andrzej Jakubowiak, Don M. Benson, William Bensinger, David S. Siegel, Todd M. Zimmerman, Ann Mohrbacher, Paul G. Richardson, Daniel Afar, Anil Singhal, Kenneth C. Anderson

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  11. 11
    A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia

    A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia by Irene M. Ghobrial, Ravi Vij, David S. Siegel, Ashraf Badros, Jonathan L. Kaufman, Noopur Raje, Andrzej Jakubowiak, Michael R. Savona, Mihaela Obreja, Jesús G. Berdeja

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition

    Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition by Mikhail A. Nikiforov, MaryBeth Riblett, W. H. Wilson Tang, Vladimir Gratchouck, Dazhong Zhuang, Yolanda Fernández, Monique Verhaegen, Sooryanarayana Varambally, Arul M. Chinnaiyan, Andrzej Jakubowiak, Marı́a S. Soengas

    Published 2007
    Get full text
    Artigo
    Save to List
    Saved in:
  13. 13
    Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant

    Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant by Benjamin A. Derman, Jennifer H. Cooperrider, Jacalyn Rosenblatt, David Avigan, Murtuza Rampurwala, David R. Barnidge, Ajay Major, Theodore Karrison, Ken Jiang, Aubrianna Ramsland, Tadeusz Kubicki, Andrzej Jakubowiak

    Published 2024
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma

    Daratumumab Improves Depth of Response and Progression-free Survival in Transplant-ineligible, High-risk, Newly Diagnosed Multiple Myeloma by Andrzej Jakubowiak, Shaji Kumar, Rohan Medhekar, Huiling Pei, Patrick Lefèbvre, Shuchita Kaila, Jianming He, Marie‐Hélène Lafeuille, Annelore Cortoos, Anil Londhe, Panagiotis Mavros, Thomas S. Lin, Saad Z. Usmani

    Published 2022
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

    Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with... by Noopur Raje, Andrzej Jakubowiak, Cristina Gasparetto, Robert F. Cornell, Heike I. Krupka, Daniel Navarro, Alison Forgie, Chandrasekhar Udata, Cynthia Basu, Jeffrey Chou, Abraham C.F. Leung, Alexander M. Lesokhin

    Published 2019
    Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

    An open‐label, single‐arm, phase 2 study of single‐agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib... by Ravi Vij, David S. Siegel, Sundar Jagannath, Andrzej Jakubowiak, Alexander K. Stewart, Kevin T. McDonagh, Nizar J. Bahlis, Andrew R. Belch, Lori Kunkel, Sandra Wear, Alvin Wong, Robert Z. Orlowski, Michael Wang

    Published 2012
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma

    Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma by Sagar Lonial, Paul G. Richardson, Jesús F. San Miguel, Pieter Sonneveld, Michael W. Schuster, Joan Bladé, Jamie Cavenagh, S. Vincent Rajkumar, Andrzej Jakubowiak, Dixie‐Lee Esseltine, Kenneth C. Anderson, Jean‐Luc Harousseau

    Published 2008
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor

    Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10–Dependent Apoptosis by Carfilzomib and Selinexor by Shaun Rosebeck, Mattina M. Alonge, Malathi Kandarpa, Anoop Mayampurath, Samuel L. Volchenboum, Jagoda Jasielec, Dominik Dytfeld, Sean P. Maxwell, Stephanie J. Kraftson, Dilara McCauley, Sharon Shacham, Michael Kauffman, Andrzej Jakubowiak

    Published 2015
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study

    Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study by Jonathan L. Kaufman, Roberto Mina, Andrzej Jakubowiak, Todd L. Zimmerman, Jeffrey Wolf, Colleen Lewis, Charise Gleason, Cathy Sharp, Thomas G Martin, Leonard T. Heffner, Ajay K. Nooka, R. Donald Harvey, Sagar Lonial

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1

    Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1 by Paul G. Richardson, Todd M. Zimmerman, Craig C. Hofmeister, Moshe Talpaz, Asher Chanan‐Khan, Jonathan L. Kaufman, Jacob P. Laubach, Dharminder Chauhan, Andrzej Jakubowiak, Steven D. Reich, Mohit Trikha, Kenneth C. Anderson

    Published 2016
    Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: